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The ataxia telangiectasia-mutated and Rad3-related
(ATR) kinase checkpoint pathway maintains genome
integrity; however, the role of the sirtuin 2 (SIRT2) ace-
tylome in regulating this pathway is not clear. We
found that deacetylation of ATR-interacting protein
(ATRIP), a regulatory partner of ATR, by SIRT2 poten-
tiates the ATR checkpoint. SIRT2 interacts with and
deacetylates ATRIP at lysine 32 (K32) in response to
replication stress. SIRT2 deacetylation of ATRIP at
K32 drives ATR autophosphorylation and signaling
and facilitates DNA replication fork progression and
recovery of stalled replication forks. K32 deacetyla-
tion by SIRT2 further promotes ATRIP accumulation
to DNA damage sites and binding to replication pro-
tein A-coated single-stranded DNA (RPA-ssDNA).
Collectively, these results support a model in which
ATRIP deacetylation by SIRT2 promotes ATR-ATRIP
binding to RPA-ssDNA to drive ATR activation and
thus facilitate recovery from replication stress, outlin-
ing a mechanism by which the ATR checkpoint is
regulated by SIRT2 through deacetylation.
INTRODUCTION
The precise replication of the genome and the continuous sur-
veillance of its integrity are essential for cell survival and the
avoidance of various diseases, including cancer and premature
aging. The genome is constantly exposed to environmental
and endogenous genotoxic insults that challenge DNA replica-
tion. To cope with this challenge, the replication stress response
(RSR), a subset of the DNA damage response (DDR), coordi-
nates diverse DNA repair and cell-cycle checkpoint signaling
pathways necessary to maintain genome integrity. The ataxia
telangiectasia mutated and Rad3-related (ATR) checkpoint ki-
nase and its regulatory partner, ATR interacting protein (ATRIP),Cell Rfunction at the apex of the RSR (Cimprich and Cortez, 2008;
Marechal and Zou, 2013; Zeman and Cimprich, 2014). ATR defi-
ciency causes embryonic lethality (Brown and Baltimore, 2000)
and premature aging in adult mice (Ruzankina et al., 2007), and
hypomorphic mutations in ATR and ATRIP are associated with
Seckel syndrome (O’Driscoll et al., 2003; Ogi et al., 2012).
Furthermore, cells lacking ATR have defects of DNA replication
(Brown and Baltimore, 2000; Cortez et al., 2001), chromosomal
instability (Casper et al., 2002), and expression of fragile sites
(Casper et al., 2002). The ATR checkpoint pathway promotes
genome integrity following replication stress through a kinase
signaling cascade that mobilizes DNA repair, causes cell-cycle
arrest, or induces apoptosis or senescence; however, the pre-
cise mechanisms by which the pathway is regulated, including
through acetylation, are not well understood.
ATR is activated by single-stranded DNA (ssDNA), resulting
from stalled replication forks (Byun et al., 2005; Sogo et al.,
2002) or processing of DNA double-strand breaks (DSBs) (Gar-
cia-Muse and Boulton, 2005; Jazayeri et al., 2006), which is then
bound by the single-stranded DNA binding protein replication
protein A (RPA) (Costanzo et al., 2003). RPA-ssDNA recruits
ATR-ATRIP through direct and indirect interactions with ATRIP
mediated by RPA-ssDNA ubiquitylation (Mare´chal et al., 2014;
Zou and Elledge, 2003), leading to the autophosphorylation of
ATR at Thr-1989 (Liu et al., 2011; Nam et al., 2011). RPA-ssDNA
also recruits the RAD17 clamp loader (Zou et al., 2003), which
loads the RAD9-HUS1-RAD1 (9-1-1) clamp complex onto DNA
(Bermudez et al., 2003) and recruits the MRE11-RAD50-NBS1
(MRN) complex (Oakley et al., 2009; Olson et al., 2007). Both the
9-1-1 complex andMRN interactwith topoisomerase II beta bind-
ing protein 1 (TopBP1), which enables it to activate ATR and stim-
ulate checkpoint signaling (Delacroix et al., 2007; Duursma et al.,
2013; Kumagai et al., 2006; Lee et al., 2007). The activation of ATR
is facilitated by the interaction of TopBP1 with ATRIP (Kumagai
et al., 2006;Mordeset al., 2008). ATRactivation is alsopotentiated
by the sumoylation of ATRIP, which promotes multiple interac-
tions in the ATR pathway (Wu et al., 2014). Once activated, ATR
phosphorylates numerous downstream substrates including the
CHK1 kinase, which helps to disperse the signal.eports 14, 1435–1447, February 16, 2016 ª2016 The Authors 1435
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Figure 1. SIRT2 Interacts in a Complex with
and Deacetylates ATRIP In Vitro and in Cells
(A and B) 293T cells were transfected with HA-A-
TRIP and/or SIRT2-FLAG, harvested, and immu-
noprecipitated with either anti-HA agarose beads
(A) or anti-Flag M2 beads (B). Bound proteins were
washed, separated by SDS–PAGE, and immuno-
blotted with antibodies against HA, Flag, and ATR.
(C and D) Endogenous ATRIP or SIRT2 was
immunoprecipitated fromHeLa cell lysates treated
with or without HU. Immunocomplexes were
washed, separated by SDS-PAGE, and immuno-
blotted with antibodies against ATRIP and SIRT2.
(E) Acetylated ATRIP was isolated from 293T cells
transfected with HA-ATRIP and histone acetyl-
transferases and incubated in an in vitro deacety-
lation assay with FLAG-SIRT2 WT or H187Y iso-
lated from 293T cells, and in the presence of TSA
with or without NAD and nicotinamide. The reac-
tion mixtures were separated by SDS-PAGE and
immunoblotted with pan-acetyl lysine, HA, and
FLAG antibodies.
(F) HeLa cells were transfectedwith HA-ATRIP and
wild-type FLAG-SIRT2 or deacetylase-inactive
FLAG-SIRT2 HY in the presence of TSA with or
without nicotinamide, immunoprecipitated with an
anti-HA antibody, separated by SDS-PAGE, and
immunoblotted with antibodies against HA, acetyl-
lysine, and FLAG.
See also Figure S1.Sirtuin 2 (SIRT2) is a member of the sirtuin family of NAD+-
dependent deacetylases, which regulate multiple biological pro-
cesses, including genome maintenance, aging, tumorigenesis,
and metabolism (Choi and Mostoslavsky, 2014; Finkel et al.,
2009; Guarente, 2011; Saunders and Verdin, 2007). There are
seven mammalian homologs of S. cerevisiae silent information
regulator 2 (Sir2). Significantly, Sirt2 overexpression prolongs
longevity in M. muscularis hypomorphic for BubR1 (North
et al., 2014), and mice deficient in Sirt2 develop breast, liver,
and other cancers (Kim et al., 2011; Serrano et al., 2013), sug-
gesting that SIRT2 functions in both aging and tumor suppres-
sion. We and others have shown that SIRT2 promotes genome
integrity (Kim et al., 2011; Serrano et al., 2013; Zhang et al.,
2013). In particular, we found that SIRT2 directs the RSR at least
in part through deacetylation of cyclin-dependent kinase 9
(CDK9) (Zhang et al., 2013), a protein required for recovery
from replication stress (Yu and Cortez, 2011; Yu et al., 2010;
Zhang et al., 2013). As sirtuins regulate networks of proteins, it
may be possible that SIRT2 directs the functions of other RSR
proteins. Indeed, a number of DDR and DNA repair proteins
have been shown to be regulated by SIRT1 and SIRT6 (Choi
and Mostoslavsky, 2014). Both ATM and DNA-dependent
protein kinase, catalytic subunit (DNA-PKcs), members of the
phosphatidylinositol 3-kinase-related kinase (PIKK) family,
which includes ATR, are regulated by acetylation (McCord
et al., 2009; Sun et al., 2005). TopBP1was also recently identified
as a SIRT1 substrate (Liu et al., 2014; Wang et al., 2014). How-1436 Cell Reports 14, 1435–1447, February 16, 2016 ª2016 The Authever, whether the SIRT2 acetylome is important for the ATR
checkpoint pathway is unclear.
In this study, we show that deacetylation of ATRIP by SIRT2
drives ATR checkpoint activation by promoting binding to
RPA-ssDNA, revealing a mechanism by which the ATR check-
point pathway is regulated by SIRT2 deacetylation, and more
generally the acetylome.
RESULTS
SIRT2 Interacts in a Complex with and Deacetylates
ATRIP In Vitro and in Cells
ATRIP was identified in a proteomic analysis for proteins that
interact with SIRT2 (data not shown). To validate the interaction
of SIRT2 and ATRIP, we performed co-immunoprecipitation (co-
IP) of HA-ATRIP and SIRT2-FLAG expressed in 293T cells. IP of
HA-ATRIP pulled down SIRT2-FLAG and endogenous ATR (Fig-
ure 1A), and reverse IP using an anti-FLAG antibody pulled down
SIRT2-FLAG, HA-ATRIP, and endogenous ATR (Figure 1B),
suggesting that the proteins interact in a complex. IP of FLAG-
ATR also pulled down SIRT2-GFP expressed in 293T cells (Fig-
ure S1A), confirming their interaction. In contrast, we failed to
detect an interaction of FLAG-SIRT1 with ATRIP or ATR by co-
IP (Figures S1B and S1C), providing evidence that the interaction
between ATR-ATRIP and SIRT2 is specific. The endogenous
interaction of SIRT2 and ATRIP was validated by a reciprocal
co-IP in HeLa cells (Figures 1C and 1D). Finally, this interactionors
showed no significant change in response to hydroxyurea (HU)
treatment (Figures 1C and 1D), suggesting that it is not regulated
by replication stress.
To determine whether SIRT2 deacetylates ATRIP, we immu-
nopurified acetylated HA-ATRIP from 293T cells and performed
an in vitro deacetylation assay with purified wild-type FLAG-
SIRT2 or FLAG-SIRT2 H187Y, a deacetylase inactive mutant
(North et al., 2003), in the presence and absence of NAD+, nico-
tinamide, an inhibitor of sirtuin activity, and TSA, a non-sirtuin
HDAC inhibitor. Wild-type FLAG-SIRT2 but not FLAG-SIRT2
H187Y deacetylated HA-ATRIP in a NAD+-dependent manner
(Figure 1E, lanes 2 and 5 versus 4), and deacetylation was in-
hibited by nicotinamide (lane 6). To determine whether SIRT2
deacetylates ATRIP in cells, we transfected HeLa cells with
HA-ATRIP and wild-type FLAG-SIRT2 or FLAG-SIRT2 H187Y.
Transfection with wild-type FLAG-SIRT2 but not FLAG-SIRT2
H187Y deacetylated HA-ATRIP in a similar manner as our cell-
free biochemical system (Figure 1F, lanes 1 and 3 versus 2), con-
firming ATRIP as a legitimate SIRT2 downstream deacetylation
target.
SIRT2 Deacetylates ATRIP at Lysine 32 in Response to
Replication Stress
To determine the specific SIRT2 downstream acetyl-lysine
target, mass spectrometry analysis was performed from immu-
nopurified HA-ATRIP expressed in 293T cells. Lysines 32, 96,
and 101, located around the amino-terminal RPA-ssDNA binding
domain (Ball et al., 2005, 2007; Namiki and Zou, 2006), were
identified as potential reversible acetyl-lysines (Figure 2A; Fig-
ures S2A–S2C). To determine whether ATRIP is acetylated at
these sites, we generated ATRIP mutants where the lysines (K)
are replaced by arginines (R), which prevent acetylation. The AT-
RIP K32R and K101R mutants and to a lesser extent the K96R
mutant were acetylated at lower levels than wild-type ATRIP as
determined by western blot analysis with an anti-acetyl-lysine
antibody (Figure 2B), suggesting that lysines K32, K96, and
K101 all contribute to acetylation of ATRIP. Moreover, overex-
presssion of FLAG-SIRT2 in cells resulted in decreased acetyla-
tion more noticeably in the K96R and K101R mutants compared
with the K32Rmutant (Figure 2B), implying that K32may be a sig-
nificant SIRT2 downstream deacetylation target.
Since K32 and its surrounding region is the most evolutionarily
conserved among the acetyl-lysine sites we identified (Figure 2A)
as well as independently identified as an acetyl-lysine site by
proteomic analysis (Hornbeck et al., 2012), we generated and
validated a rabbit monoclonal anti-acetyl ATRIP K32 antibody.
This antibody recognizes acetylated endogenous ATRIP and
exogenous tagged wild-type HA-ATRIP, but not HA-ATRIP
K32R expressed in HCT-116 cells where these bands are also
recognized by an anti-ATRIP antibody, as determined by west-
ern blot analysis (Figure S2D). The specificity of the anti-acetyl
ATRIP K32 antibody for endogenous ATRIP in HCT-116 cells
was also validated by small interfering RNA (siRNA) knockdown
(Figure S2E). To determine whether ATRIP is acetylated at K32 in
cells and further regulated by sirtuin or HDAC deacetylation,
HCT-116 cells stably transfected with HA-ATRIP were treated
with nicotinamide or TSA. Lysine 32 was acetylated in the
absence of treatment, and the level of acetylation was increasedCell Rto a similar extent with nicotinamide or TSA treatment (Fig-
ure S2F), suggesting that K32 is acetylated in untreated cells
and can be regulated by both sirtuin and HDAC deacetylation.
Consistent with the results of our interaction studies (Figures
S1B and S1C), FLAG-SIRT2, but not FLAG-SIRT1, deacetylated
HA-ATRIP expressed in 293T cells at K32 (Figure 2C), implying
that SIRT2 deacetylates ATRIP at K32.
To determine whether ATRIP deacetylation is regulated by
replication stress, we analyzed the acetylation of HA-ATRIP ex-
pressed in 293T cells treated with or without HU. Western blot
analysis with an anti-acetyl-lysine antibody of HA-ATRIP immu-
noprecipitated from 293T cells (Figure 2D) and co-immunopre-
cipitated with SIRT2-FLAG from cells (Figure S2G) showed a
significant decrease in acetylation of ATRIP from HU-treated
cells compared to non-treated cells. HA-ATRIP from 293T cells
were also deacetylated specifically at K32 in response to HU
and camptothecin (CPT) treatment (Figures 2E and 2F). More-
over, a mild decrease in K32 acetylation was observed following
ionizing radiation (IR) treatment of 293T cells synchronized pre-
dominantly in S-phase but not G1 phase (Figure S2H) suggesting
that ATRIP is deacetylated at K32 after IR in cells that support
DNA end resection, RPA binding.
To determine whether endogenous ATRIP K32 is deacetylated
by SIRT2 in response to replication stress, we analyzed the
acetylation of ATRIP in HCT-116 cells transfected with SIRT2
or non-targeting (NT) siRNAs and treated with or without HU.
Endogenous ATRIP was acetylated at K32 in the absence of
treatment and deacetylated at K32 after HU treatment, and,
importantly, the HU-regulated deacetylation of ATRIP at K32
was alleviated by SIRT2 depletion (Figure 2G), suggesting that
ATRIP is present in the acetylated form at K32 in cells and is sub-
sequently deacetylated by SIRT2 in response to replication
stress.
To further investigate what triggers SIRT2-dependent deace-
tylation of ATRIP K32, we performed an in vitro deacetylation
assay using acetylated-ATRIP as a substrate and SIRT2 purified
from 293T cells treated with or without HU. Increased deacetyla-
tion of the substrate using SIRT2 purified from cells treated with
HU compared with no treatment was observed (Figure 2H), sug-
gesting that SIRT2 deacetylase activity increases in response to
replication stress.
SIRT2 Promotes ATR Activation
To determine whether SIRT2 directs ATR activity, we examined
HCT-116 cells transfected with SIRT2 or a non-targeting (NT)
siRNA and treated with or without HU for ATR autophosphoryla-
tion at Thr1989, amarker for ATR activation (Liu et al., 2011; Nam
et al., 2011). SIRT2 depletion significantly reduced ATR auto-
phosphorylation, but not total ATR levels, in response to HU
treatment (Figure 3A), suggesting that SIRT2 promotes ATR acti-
vation in response to replication stress. To determine whether
SIRT2 functions in ATR-dependent signaling, we examined
HCT-116 cells for phosphorylation of a panel of ATR substrates
in response to HU treatment. SIRT2 depletion reduced the HU-
induced phosphorylation of RAD17 Ser645, CHK1 Ser317, and
p53 Ser15 (Figure 3B). No significant difference in percentage
of cells in S-phase was observed following SIRT2 depletion (Fig-
ure S3A), suggesting that the effects of SIRT2 depletion on ATReports 14, 1435–1447, February 16, 2016 ª2016 The Authors 1437
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Figure 2. SIRT2 Deacetylates ATRIP at K32 in Response to Replication Stress
(A) Clustal Omega and BoxShade were used to align ATRIP protein sequences from the indicated organisms. The positions of the acetylated residues K32, K96,
and K101 are depicted relative to the domains of ATRIP.
(B) 293T cells were transfected with wild-type ATRIP or deacetylated mutants ATRIP K32R, ATRIP K96R, or ATRIP K101R and histone acetyltransferases with or
without FLAG-SIRT2 in the presence of TSA, immunoprecipitated with anti-HA beads, separated by SDS-PAGE, and immunoblotted with antibodies against HA,
acetyl-lysine, and FLAG.
(C) 293T cells were transfected with HA-ATRIP and histone acetyltransferases, together with vector or FLAG-SIRT1 or FLAG-SIRT2 in the presence of TSA,
harvested, separated by SDS-PAGE, and immunoblotted with antibodies against Ac-ATRIP K32, HA, Flag, and GAPDH.
(D–F) 293T cells were transfected with HA-ATRIP and histone acetyltransferases, treated with or without HU or CPT in the presence of TSA, harvested for whole-
cell lysates (F) or immunoprecipitatedwith anti-HA beads (D and E), separated by SDS-PAGE, and immunoblotted with antibodies against acetyl-lysine (D) or anti-
Ac-ATRIP K32 (E and F) and HA.
(G) HCT116 transfected with SIRT2 or NT siRNA were treated with or without HU in the presence of TSA, harvested, immunoprecipitated with an anti-ATRIP
antibody, separated by SDS-PAGE, and immunoblotted with antibodies against Ac-ATRIP K32, ATRIP, SIRT2, and GAPDH.
(H) Acetylated ATRIP was isolated from 293T cells transfected with HA-ATRIP and histone acetyltransferases (p300/CBP and pCAF) and incubated in an in vitro
deacetylation assay with FLAG-SIRT2WT isolated from 293T cells treated with or without HU, in the presence of TSA with or without NAD and nicotinamide. The
reaction mixtures were separated by SDS-PAGE and immunoblotted with Ac-ATRIP K32, HA, and FLAG antibodies.
See also Figure S2.activation are likely not due to changes in cell cycle. The effects
of SIRT2 depletion on ATR Thr1989 andCHK1Ser317 phosphor-
ylation following HU treatment were also observed with an inde-
pendent siRNA targeting the 30 UTR of SIRT2 (Figure S3B), and,
significantly, expression of FLAG-SIRT2 rescued the impairment
in CHK1 Ser317 phosphorylation following depletion of endoge-
nous SIRT2 (Figure 3C).
ATRIP Acetylation at Lysine 32 Impairs ATR
Autophosphorylation and Signaling
To assess the functional significance of ATRIP acetylation, we
generated ATRIP mutants in which K32, K96, or K101 was re-
placed by glutamine to mimic an acetylated lysine state. 293T1438 Cell Reports 14, 1435–1447, February 16, 2016 ª2016 The Authcells expressing HA-ATRIP K32Q, at least to a greater degree
than K96Q or K101Q, showed an impairment in ATR autophos-
phorylation, as compared to wild-type HA-ATRIP following HU
treatment (Figure 3D), suggesting that the acetylation status of
ATRIP at K32, but not lysine 96 or lysine 101, is most critical for
ATR activation. Indeed, significant impairment in ATR auto-
phosphorylation was observed only in cells expressing HA-AT-
RIP K32Q, but not HA-ATRIP K32R or wild-type HA-ATRIP
(Figure 3E). Moreover, cells expressing HA-ATRIP K32Q but
not wild-type HA-ATRIP showed an impairment in ATR-depen-
dent phosphorylation of RAD17 at Ser645 in response to HU
treatment (Figure S3C). No significant difference in percentage
of S-phase cells was observed in these cells (Figure S3D),ors
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Figure 3. SIRT2 Deacetylation of ATRIP at K32 Promotes ATR Activation
(A) HCT116 cells were transfected with NT or SIRT2 siRNA, treated with or without HU, harvested, immunoprecipitated with an anti-ATR antibody, separated by
SDS-PAGE, and immunoblotted with antibodies against P-ATR T1989, ATR, SIRT2, and GAPDH.
(B) HCT116 cells were transfected with NT or SIRT2 siRNA, treated with or without HU, harvested, separated by SDS-PAGE, and immunoblotted with indicated
antibodies.
(C) Cells stably expressing an empty vector or FLAG-SIRT2 and transfected with NT or SIRT2 siRNA targeting the 30 UTR were treated with or without HU,
harvested, separated by SDS-PAGE, and immunoblotted with indicated antibodies.
(D) 293T cells were transfected with ATRIPWTor K32Q, K96Q, or K101Q, treatedwith or without HU, immunoprecipitatedwith anti-HA beads, separated by SDS-
PAGE, and immunoblotted with antibodies against HA, P-ATR T1989, and ATR.
(E) 293T cells were transfected with ATRIP WT or K32R or K32Q, treated with or without HU, and extracted for nuclear extraction. The nuclear extraction was
separated by SDS-PAGE and immunoblotted with antibodies against HA, P-ATR T1989, and ATR.
(F) HCT-116 cells stably expressing an empty vector or HA-ATRIP WT or K32Q and transfected with NT or SIRT2 siRNA were treated with or without HU,
harvested, separated by SDS-PAGE, and immunoblotted with indicated antibodies.
See also Figure S3.
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suggesting that the effects of K32 acetylation on ATR activation
are not likely cell cycle related. Of further note, HA-ATRIP K32Q
co-immunoprecipitated a similar amount of ATR as wild-type
HA-ATRIP (Figure 3D), suggesting that ATRIP acetylation at
K32 does not impair its interaction with ATR. Finally, expression
of HA-ATRIP wild-type (WT) but not K32Q alleviated the impair-
ment in HU-induced ATR autophosphorylation and CHK1
Ser317 phosphorylation following SIRT2 depletion (Figure 3F),
strongly suggesting that the effects of SIRT2 depletion on
ATR activation are mediated through K32 deacetylation.
Collectively, these findings suggest that acetylation of ATRIP
at K32 impairs ATR activation and deacetylation of ATRIP at
K32 by SIRT2 promotes ATR activation in response to replica-
tion stress.
ATRIP Acetylation at Lysine 32 Impairs DNA Replication
Fork Progression and Recovery of Stalled Replication
Forks
To determine whether ATRIP acetylation at K32 is critical for re-
covery from replication stress, we examined U2OS cells stably
expressing vector or siRNA-resistant HA-ATRIP wild-type,
K32Q, K96Q, or K101Q and transfected with NT or ATRIP siRNA
(Figures S4A and S4B) for cell-cycle recovery following HU treat-
ment. Cells expressing HA-ATRIP K32Q showed the greatest
impairment in HU recovery compared with cells expressing
wild-type HA-ATRIP WT or HA-ATRIP K96Q and K101Q and
silenced for endogenous ATRIP (Figures S4C and S4D), sug-
gesting that the acetylation status of K32 is the most critical for
recovery from replication stress. The impairment in HU recovery
of cells expressing HA-ATRIP K32Q was present even in the
absence of endogenous ATRIP depletion, suggesting that the
K32Q mutant can act in a dominant-negative manner.
To further determine whether K32 acetylation is important for
replication fork progression, we used DNA fiber labeling to
directly measure DNA replication fork dynamics. Newly synthe-
sized DNA was labeled with 50 iododeoxyuridine (IdU) for
20 min followed by 50-chlorodeoxyuridine (CldU) for 20 min in
cells before DNA fiber spreads were processed by indirect
immunofluorescence. Consistent with findings using an ATR in-
hibitor (Couch et al., 2013), cells expressing HA-ATRIP K32Q
demonstrated decreased CldU fiber length, as compared with
cells expressing wild-type HA-ATRIP or HA-ATRIP-K32R (Fig-
ures 4A and 4B), implying that K32 acetylation decreases repli-
cation fork elongation. To determine whether K32 acetylation is
involved in recovery of DNA synthesis after replication fork
arrest, we labeled cells with IdU, blocked DNA replication
with HU, washed out the drug, and labeled the cells with CldU.
Cells expressing HA-ATRIP-K32Q demonstrated a significant
decrease in CldU fiber length (Figures 4C and 4D) as well as a
significant increase in replication tracks with no CldU uptake af-
ter HU release (Figure 4E), indicative of collapsed replication
forks that cannot restart, compared with cells expressing wild-
type HA-ATRIP or HA-ATRIP-K32R, suggesting that K32 acety-
lation impairs DNA replication fork restart following replication
arrest. Similar to findings with an ATR inhibitor (Couch et al.,
2013), cells expressing HA-ATRIP-K32Q but not wild-type or
K32R also showed an increase in replication origin initiation (Fig-
ure 4F). Collectively, these findings demonstrate that ATRIP K321440 Cell Reports 14, 1435–1447, February 16, 2016 ª2016 The Authacetylation impairs DNA replication fork progression and recov-
ery of stalled replication forks.
To determine whether K32 acetylation is important for medi-
ating sensitivity following replication stress, we examined for
cell viability following a course of CPT treatment. Expression of
wild-type HA-ATRIP and HA-ATRIP K32R but not K32Q signifi-
cantly increased the percent viability of U2OS cells silenced for
endogenous ATRIP by siRNA following CPT treatment (Fig-
ure S4E), suggesting that ATRIP K32 deacetylation promotes
response to replication stress.
Lysine 32 Acetylation Impairs ATRIP Accumulation to
Sites of DNA Damage
To determine how ATRIP acetylation affects ATR activation, we
investigated whether K32 acetylation is critical for localization of
ATRIP to sites of DNA damage. Both wild-type GFP-ATRIP and
GFP-ATRIP-K32R expressed in HeLa cells localized to DNA
damage foci in response to HU and ionizing radiation (IR) treat-
ment (Figures 5A–5C). In contrast, GFP-ATRIP-K32Q showed a
significant decrease in DNA damage foci formation (Figures
5A–5C), suggesting that K32 acetylation impairs ATRIP localiza-
tion to sites of DNA damage. In addition, cells expressing GFP-
ATRIP-K32Q showed a decrease in formation of DNA damage
foci that co-localize with RPA70, as compared with cells ex-
pressing wild-type GFP-ATRIP or GFP-ATRIP-K32R (Figures
5D–5F), despite similar formation of RPA70 foci following DNA
damage in GFP-ATRIP-expressing cells (Figures S5A and S5B)
and similar cell-cycle profiles (Figure S5C), suggesting that
K32 acetylation impairs the recruitment of ATRIP to DNA dam-
age sites marked by RPA70. Western blot analysis confirmed
expression of wild-type GFP-ATRIP and the GFP-ATRIP-K32R
and -K32Q mutants (Figure S5D).
To determine whether SIRT2 is required for the localization of
ATRIP to sites of DNA damage, we examined for the localization
of HA-ATRIP expressed in mouse mammary tumor Sirt2
knockout (MMT S2KO) cells (Kim et al., 2011) complemented
with or without wild-type SIRT2 and treated with or without
HU. MMT S2KO cells expressing wild-type HA-ATRIP showed
a significant impairment in foci formation in response to HU treat-
ment comparedwithMMTS2KO cells expressingHA-ATRIP and
complemented with wild-type SIRT2 (Figures 5G, cf. rows 1 and
3, 5H, and S5E). The impairment in HA-ATRIP foci formation in
MMT S2KO cells was comparable to that of HA-ATRIP K32Q ex-
pressed inMMTS2KO cells complementedwith wild-type SIRT2
(Figure 5G, cf. rows 3 and 2) and moreover was partially rescued
by the expression of HA-ATRIP K32R in MM2 S2KO cells (Fig-
ures 5G, row 4, and 5H), suggesting that K32 deacetylation by
SIRT2 in response to replication stress promotes ATRIP accu-
mulation to sites of DNA damage.
SIRT2 Deacetylation of ATRIP at Lysine 32 Promotes
Binding to RPA-ssDNA
The efficient activation of ATR requires its association with RPA-
ssDNA at sites of DNA damage through ATRIP. Our observation
that K32 acetylation impairs the recruitment of ATRIP to sites of
DNA damage that co-localize with RPA70, as well as the location
of K32 near the amino-terminal RPA-ssDNA binding domain of
ATRIP, suggest that K32 acetylation directs its interaction withors
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Figure 4. ATRIP Acetylation at K32 Impairs DNA Replication Fork Progression and Recovery from Replication Arrest
(A and B) 293T cells transfected with HA-ATRIP WT, K32R, or K32Q were labeled with IdU for 20 min and then with CldU for 20 min in the presence of DMSO or
5 mM ATRi during both labeling periods before harvesting for DNA fiber labeling.
(A) Representative replication tracks and distribution of the lengths of CldU (red) tracks in dual-labeled tracks are shown. p < 0.01 WT compared to K32Q by
Mann-Whitney U test.
(B) Median, first quartile, third quartile, and interquartile range of the lengths of CldU tracks in dual-labeled tracks are shown.
(C–F) 293T cells transfected withWT, K32R, or K32Q ATRIP were labeled with IdU for 20min treated with 2mMHU for 1 hr in the presence of DMSO or 5 mMATRi
and then labeled with CldU for 20 min before harvesting for fiber staining.
(C) Representative replication tracks and distribution of the lengths of CldU tracks in dual-labeled tracks are shown. p < 0.01 WT compared to K32Q by Mann-
Whitney U test.
(D) Median, first quartile, third quartile, and interquartile range of the lengths of CldU tracks in dual-labeled tracks is shown.
(E) Percentage of collapsed forks (green-only tracks) following HU treatment is compared.
(F) Percentage of newly initiated origins (red-only tracks) following HU treatment is compared. In all experiments, data were collected from several replicates with
high-quality DNA fibers with at least 100 fibers counted for lengths and 300 fibers counted for collapsed fork and origins. *p < 0.05, **p < 0.01.
See also Figure S4.RPA-ssDNA. As such, co-IP of HA-ATRIP with endogenous
RPA70 and RPA32 in HeLa cells was significantly decreased
following SIRT2 depletion (Figure 6A), suggesting that SIRT2
enhances the interaction of ATRIP with RPA in cells. In contrast,
we observed no significant change in the amount of HA-ATRIP
co-immunoprecipitated with ATR, TopBP1, or NBS1 followingCell RSIRT2 depletion (Figure 6A), consistent with our finding that
acetylation of ATRIP does not alter its interaction with ATR (Fig-
ure 3D). In a reciprocal manner, the co-IP of HA-ATRIP with
RPA70 and RPA32, but not ATR, in 293T cells was significantly
increased following SIRT2 overexpression (Figure S6A). To
determine whether acetylation at K32 is critical for the interactioneports 14, 1435–1447, February 16, 2016 ª2016 The Authors 1441
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Figure 5. K32 Acetylation Impairs ATRIP Accumulation to Sites of DNA Damage
HeLa cells were transfected withWT, K32R, or K32QGFP-ATRIP, respectively. Cells were either treated with 10 Gy IR and allowed 4 hr to recover or cultured with
3 mM HU for 24 hr before RPA70 staining for immunofluorescence analysis.
(A) Representative cell nuclei with GFP-ATRIP foci formation in response to IR and HU treatment are shown.
(B and C) The percentage of GFP-ATRIP foci positive cells from three replicate experiments are separately shown for IR treatment (B) and HU treatment (C).
(D) Representative cell nuclei with both RPA and GFP-ATRIP foci formation in response to IR and HU treatment are shown.
(EandF)ThepercentageofRPA+GFP-ATRIP focidouble-positivecells fromthree replicateexperimentsareseparately shown for IR treatment (E)andHUtreatment (F).
(G) Representative cell nuclei with HA-ATRIP foci formation in response to HU treatment in MMT Sirt2 KO cells complemented with or without SIRT2 WT.
(H) The average number of HA-ATRIP foci following HU treatment from three replicate experiments is shown. **p < 0.01.
See also Figure S5.
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Figure 6. SIRT2 Deacetylation of ATRIP at K32 Promotes Binding to RPA-ssDNA
(A) HeLa cells stably expressing SIRT2 or control shRNA were transfected with HA-ATRIP and treated with HU in the presence of TSA, harvested, immuno-
precipitated with anti-HA beads, separated by SDS-PAGE, and immunoblotted with antibodies against ATR, TopBP1, NBS1, HA, RPA70, RPA32, and SIRT2.
(B–D) HA-ATRIP expressed in 293T cells was incubated with biotinylated ssDNA bound to streptavidin beads with or without recombinant RPA for 2 hr. Bound
proteins were washed, separated by SDS-PAGE, and immunoblotted with the indicated antibodies.
(B) RPA-ssDNA binding assay for HA-ATRIP WT expressed in 293T cells and transfected with SIRT2 or control siRNA.
(C) RPA-ssDNA binding assay for HA-ATRIP WT purified from 293T cells treated with or without HU.
(D) RPA-ssDNA binding assay for HA-ATRIP WT, K32R, or K32Q purified from 293T cells.
(E) Recombinant GST-ATRIP 1–107WT, K32R, or K32Qwas incubated with biotinylated ssDNA bound to streptavidin beads with or without recombinant RPA for
2 hr. Bound proteins were washed, separated by SDS-PAGE, and immunoblotted with the indicated antibodies.
See also Figure S6.
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ATRIP deacetylation at K32 by SIRT2 promotes its binding to RPA-ssDNA,
driving ATR activation, thus facilitating recovery from replication stress.of ATRIP with RPA, we performed co-IP of HA-ATRIP K32R and
K32Q in HeLa cells. A significant decrease in interaction of
RPA70 but not ATR with HA-ATRIP K32Q compared with K32R
was observed (Figure S6B), suggesting that acetylation at K32
impairs the interaction of ATRIP with RPA.
To determine whether SIRT2 specifically affects the binding of
ATRIP to RPA-ssDNA, we performed an in vitro RPA-ssDNA
binding assay with biotinylated ssDNA coated with or without
bacterial purified recombinant trimeric RPA (Figure S6C) and
wild-type HA-ATRIP expressed in 293T cells transfected with
SIRT2 or control siRNA. The binding of wild-type HA-ATRIP to
RPA-ssDNA was significantly decreased following SIRT2 deple-
tion (Figure 6B), suggesting that SIRT2 promotes the binding of
ATRIP to RPA-ssDNA. The binding of wild-type HA-ATRIP puri-
fied from 293T cells to RPA-ssDNA was also significantly
enhanced following treatment of the cells with HU (Figure 6C),
which correlated with a decrease in acetylation of K32 (Fig-
ure 2E). To determine whether K32 acetylation affects the bind-
ing of ATRIP to RPA-ssDNA, we examined wild-type HA-ATRIP,
HA-ATRIP-K32R, or HA-ATRIP-K32Q expressed in cells treated
with or without HU with RPA-ssDNA. The binding of HA-ATRIP-
K32Q to RPA-ssDNA was significantly impaired compared with
wild-type HA-ATRIP and HA-ATRIP-K32R both in the absence
and presence of HU treatment (Figures 6D and S6D), suggesting
that K32 acetylation impairs the binding of ATRIP with RPA-
ssDNA. A conserved acidic checkpoint recruitment domain of1444 Cell Reports 14, 1435–1447, February 16, 2016 ª2016 The AuthATRIPmapped to amino acids 54–70 has previously been shown
to interact with a basic cleft in RPA (Ball et al., 2007; Feldkamp
et al., 2013; Souza-Fagundes et al., 2012). As K32 lies just
outside this domain, whether the acetylation of ATRIP at K32 is
critical for mediating a direct or indirect interaction, i.e., through
another protein, with RPA-ssDNA is not clear. Thus, we exam-
ined the binding of recombinant wild-type and mutant ATRIP
aa 1–107 purified from bacteria (Figure S6E) with recombinant
RPA-ssDNA. ATRIP 1–107 has been shown to be sufficient for
binding to RPA-ssDNA (Ball et al., 2007). Similar to full-length AT-
RIP K32Q, recombinant ATRIP 1–107 K32Q purified from bacte-
ria showed a significant impairment in binding with RPA-ssDNA
compared with ATRIP 1–107 wild-type and K32R (Figure 6E),
suggesting that K32 deacetylation likely promotes a direct inter-
action with RPA-ssDNA. No significant difference in interaction
of recombinant ATRIP 1–107 K32Q with ssDNA alone compared
ATRIP 1–107 wild-type or K32R was observed (Figure 6E).
Collectively, these findings imply that deacetylation of ATRIP at
K32 by SIRT2 in response to replication stress promotes its
direct binding to RPA-ssDNA.
DISCUSSION
Our results describe a mechanism for regulation of the ATR
checkpoint pathway whereby ATRIP deacetylation by SIRT2
drives ATR checkpoint activation by promoting binding to
RPA-ssDNA. In this regard, we found that SIRT2 interacts with
and deacetylates ATRIP at K32 in response to replication stress,
providing evidence that ATR-ATRIP is regulated by SIRT2 de-
acetylation and indicating that ATRIP is an interacting partner
and substrate for SIRT2. We further found that SIRT2 deacetyla-
tion of ATRIP at K32 drives ATR autophosphorylation and
signaling and facilitates DNA replication fork progression and re-
covery of stalled replication forks following replication stress,
demonstrating that SIRT2 functions as an important regulator
of ATR activity and helping to explain why Sirt2 deficiency results
in genomic instability and cancer development. Finally, we found
that K32 deacetylation by SIRT2 promotes ATRIP accumulation
to sites of DNA damage and binding to RPA-ssDNA, providing a
mechanistic model for how ATRIP deacetylation by SIRT2 drives
ATR activation. In this model, replication stress activates SIRT2
and triggers SIRT2 deacetylation of ATRIP at K32, which pro-
motes its recruitment and binding to RPA-ssDNA thus driving
ATR activation and facilitating DNA replication fork progression
and recovery from replication stress (Figure 7).
Our finding that SIRT2 promotes the interaction of ATRIP with
RPA but not with ATR, TopBP1, or NBS1 suggests that ATRIP
deacetylation by SIRT2 is a distinct mechanism for mediating
the interaction of ATRIP specifically with RPA in contrast to the
sumoylation of ATRIP at K234 and K289, which promotes its
interaction with multiple partners in the ATR signaling pathway
(Wu et al., 2014). We also found that ATRIP is deacetylated in
response to HU, CPT, and IR treatment, whereas ATRIP sumoy-
lation does not increase in response to HU treatment, suggesting
that ATRIP acetylation and sumoylation may be complementary
mechanisms for regulation of ATR activation. In this regard, it is
important to note that ATRIP acetylation is also critical for medi-
ating its binding specifically to RPA-ssDNA, which is induced byors
DNA damage and replication stress and may have distinct bind-
ing properties from free RPA.
A conserved acidic checkpoint recruitment domain for ATRIP,
mapped to amino acids 54–70, has previously been shown to
interact with a basic cleft in RPA (Ball et al., 2007; Feldkamp
et al., 2013; Souza-Fagundes et al., 2012). Since K32 lies just
outside this domain, our observation that acetylation of K32 in
a recombinant fragment of ATRIP 1–107 impairs binding to
RPA-ssDNA suggest that K32 deacetylation may promote a
direct interaction with RPA-ssDNA through a different interface
or possibly by inducing a conformational change. Indeed, the
interaction of RPAwith associated proteins often occurs through
at least two interfaces and can be influenced by conformational
changes induced by ssDNA binding (Bochkareva et al., 2001).
Importantly, K32 deacetylation as a mechanism for promoting
the interaction of ATRIP with RPA-ssDNA is regulated by replica-
tion stress, consistent with a previous observation of an increase
in the binding of ATRIP with RPA-ssDNA following UV treatment
(Namiki and Zou, 2006).
Our observation that K32 acetylation only partially impairs
ATRIP localization to RPA foci and binding with RPA-ssDNA sug-
gests that there may be additional mechanisms for regulation of
ATRIP localization and binding with RPA. While the amino-termi-
nal domain of ATRIP is required for its localization to DNA dam-
age foci (Ball et al., 2005; Itakura et al., 2004), ATRIP also makes
additional contacts with RPA-ssDNA outside its amino-terminal
domain (Namiki and Zou, 2006). Thus, it is possible that these
sites may contribute to the stabilization of the interaction of
ATRIP with RPA-ssDNA, perhaps facilitated by ATRIP sumoyla-
tion. In addition, the relativelymodest defect in ATRIP localization
comparedwith ATR activation with K32 acetylation suggests that
the defect in ATR activation with ATRIP acetylation cannot be
fully accounted for by a defect in ATRIP localization and may
be more closely linked with the defect in binding of
ATRIP with RPA-ssDNA. A similar discrepancy between ATRIP
localization with ATR activation has also previously been
reported (Ball et al., 2005; Wu et al., 2014). Thus, these data pro-
vide further support for the notion that ATR activity is more
closely linked with RPA-ssDNA binding than with ATR-ATRIP
localization.
Although we found that ATRIP is also acetylated at K96 and
K101, we did not observe a significant impairment in ATR auto-
phosphorylation or CHK1 phosphorylation in response to repli-
cation stress with K96 or K101 acetylation compared with K32
acetylation, suggesting that K32, but not K96 or K101, directs
ATR activation. However, K96 and K101 acetylation causes a
partial impairment in cell-cycle recovery following replication
stress, suggesting that they may also regulate important bio-
logical functions in the RSR in parallel or downstream of ATR
activation. Interestingly, both sites are adjacent to the coiled-
coil domain of ATRIP as well as a region of ATRIP that is
capable of binding ssDNA by itself in the absence of RPA.
While our data identify SIRT2 is a major driver of K32 deacety-
lation in response to replication stress, an increase in acetyla-
tion of K32 was also observed following TSA treatment,
suggesting that K32 may also be regulated by HDACs. The
near complete deacetylation of HA-ATRIP K32 by SIRT2 over-
expression in cells even in the presence of HDAC inhibition withCell RTSA suggests that SIRT2 is sufficient for K32 deacetylation,
and the alleviation of the HU-regulated deacetylation of endog-
enous ATRIP K32 by SIRT2 depletion even in the presence of
HDAC inhibition with TSA suggests that the HU-regulated de-
acetylation of ATRIP at K32 occurs in an HDAC-independent
manner, and that SIRT2 plays a major role in deacetylating
K32 in response to replication stress, although we cannot
exclude a role for HDACs in also regulating ATRIP activity in
this context. The interplay of multiple HDACs and sirtuins or
even of different sirtuins in regulating a single substrate is
poorly understood but may provide an additional layer of con-
trol of ATR-ATRIP function through regulation of acetylation
dynamics.
We previously found that SIRT2 directs the RSR at least in part
through deacetylation of CDK9 (Zhang et al., 2013). Our identifi-
cation of ATRIP as a binding partner and substrate of SIRT2 pro-
vides further validation for SIRT2 as an important regulator of the
RSR and ATRIP as an additional downstream SIRT2 substrate in
promoting the RSR. Although CDK9 overexpression can fully
complement the HU hypersensitivity of SIRT2 depletion in cells,
the HU-regulated deacetylation of CDK9 that requires SIRT2 is
alleviated by ATR depletion (Zhang et al., 2013), suggesting
that the effects of SIRT2 on CDK9 activity may be both direct
through deacetylating CDK9 and indirect through deacetylating
ATRIP. We speculate that SIRT2 likely regulates acetylome net-
works involved in maintaining genome integrity in response to
replication stress. Whatmight trigger SIRT2-dependent deacety-
lation of its downstream substrates in response to replication
stress? One mechanism may be through regulating its deacety-
lase activity, which we found increases in response to replication
stress. Sirt2 deficiency in mice leads to breast, liver, and other
cancers (Kim et al., 2011; Serrano et al., 2013). Our identification
of the ATR checkpoint signaling pathway as a SIRT2 target
provides one possible explanation for how SIRT2 dysregulation
leads to genomic instability and ultimately cancer development.
In summary, our results support a model in which ATRIP
deacetylation by SIRT2 promotes ATR-ATRIP recruitment and
binding to RPA-ssDNA to drive ATR activation and thus facilitate
recovery from replication stress, revealing a unique mechanism
by which the ATR checkpoint is regulated through deacetylation
by SIRT2.
EXPERIMENTAL PROCEDURES
Cell Culture
HumanHEK293T, HeLa, HCT116, andU2OS andMMTS2KOcells were grown
in Dulbecco’s modified Eagle medium (DMEM, Gibco) supplemented with
7.5% fetal bovine serum. Stably transfected HCT116, HeLa, and U2OS cells
were maintained in standard medium containing 1 mg/ml puromycin (Fisher).
Transfections, Deacetylation, Immunofluorescence, IP/Westerns,
DNA Replication, RPA-ssDNA Pull Down, and Mass Spectrometry
Details of these methodologies can be found in Supplemental Experimental
Procedures.
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